Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow has successfully leveraged its compounding pharmacy to drive rapid branded drug growth. My valuation suggests substantial upside if growth continues. Read the full stock analysis.

Harrow's CEO Mark Baum transforms a struggling company into a leader in ophthalmic drugs, with growth in branded products & regulatory risk mitigation. Read more here.

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Moreover, HROW is currently trading at 98.4% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.